Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was 309.06B DKK, up 6.4% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is 309.06B DKK in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 309.06B DKK | +6.4% |
| FY2024 | Dec 31, 2024 | 290.40B DKK | +25.0% |
| FY2023 | Dec 31, 2023 | 232.26B DKK | +31.3% |
| FY2022 | Dec 31, 2022 | 176.95B DKK | +25.7% |
| FY2021 | Dec 31, 2021 | 140.80B DKK | +10.9% |
| FY2020 | Dec 31, 2020 | 126.95B DKK | +4.0% |
| FY2019 | Dec 31, 2019 | 122.02B DKK | +9.1% |
| FY2018 | Dec 31, 2018 | 111.83B DKK | +0.1% |
| FY2017 | Dec 31, 2017 | 111.70B DKK | -0.1% |
| FY2016 | Dec 31, 2016 | 111.78B DKK | +3.6% |
| FY2015 | Dec 31, 2015 | 107.93B DKK | – |
See a number that looks wrong?